One rare outcome that gained significant attention was that of ESA-induced pure red cell aplasia (PRCA) between 1998 and 2004, mainly associated with the subcutaneous (SC) route of administration, and the exact cause of which is thought to be the production of anti-EPO antibodies. The gene discussed is EPO; the disease is pure red-cell aplasia.